Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 11/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448859 | 0.92 | KIT (0.58) | FYNCHEK2BRD4GAKKIT | |
| SCHEMBL17144935 | 0.92 | KDM4E (0.53) | FYNBRD4GAKKITTGFBR1 | |
| SCHEMBL9971233 | 0.90 | FYN (0.52) | FYNCHEK2BRD4GAKKIT | |
| SCHEMBL502835 | 0.90 | FYN (0.56) | FYNCHEK2BRD4GAKMAP3K11 | |
| SCHEMBL13881650 | 0.85 | TSHR (0.52) | FYNBRD4GAKKITTGFBR1 | |
| SCHEMBL14983301 | 0.85 | PDE5A (0.47) | FYNCHEK2BRD4GAKTGFBR1 | |
| SCHEMBL502772 | 0.84 | FYN (0.47) | FYNCHEK2BRD4GAKKIT | |
| SCHEMBL9968588 | 0.84 | FYN (0.47) | FYNCHEK2BRD4GAKKIT | |
| SCHEMBL5206468 | 0.83 | PDGFRB (0.49) | FYNBRD4KIT | |
| SCHEMBL17144646 | 0.83 | IDO1 (0.50) | FYNBRD4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | claimed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | claimed |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20130137869-A1 | LUMINOPHORES | UNIVERSITY OF YORK (UK) | 2013-05-30 | — | — | US | disclosed |
| EP-2547748-A1 | LUMINOPHORES | University of York (GB) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011114095-A1 | LUMINOPHORES | UNIVERSITY OF YORK (GB) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | FLT4, TUBB3, TUBA4A | FYN 2592/4885CHEK2 1137/4885BRD4 198/4885 |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | FLT4, TUBB3, TUBA4A | FYN 2592/4885CHEK2 1137/4885BRD4 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.